Image 3_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.jpeg by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Image 5_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.jpeg by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Table 3_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.xlsx by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Table 9_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.xlsx by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Table 8_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.xlsx by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Image 2_Single-cell transcriptomics reveals the heterogeneity and function of mast cells in human ccRCC.jpeg by Xiyu Song (14914467)

“…The overall percentage of activated MCs in ccRCC tissues did not change significantly but shifted toward a more activated subpopulation (VEGFA⁺ MCs), with a concomitant decrease in proliferative MCs (TNF⁺ MCs) and resting MCs. …”

Data Sheet 1_Unveiling the effects of land use and intra-seasonal variation on bee and plant diversity and their ecological interactions in vegetation surrounding coffee plantation... by Quebin Bosbely Casiá-Ajché (14234267)

“…Additionally, we observed higher visit frequency and richness of bees and plant generality during the second period of the rainy season (July to October), leading to more robust bee–plant interaction networks in the same period. …”

Table 1_Association between estimated glucose disposal rate and the risk of atherosclerotic cardiovascular disease: insight from cross-sectional and retrospective cohort studies.do... by Zixuan Wang (35190)

“…</p>Results<p>A significant negative linear association between eGDR and ASCVD risk was observed in our study. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

DataSheet1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.pdf by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Table 1_Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.docx by Xinhui Yang (12051251)

“…Intragroup analysis indicated a significant decrease in TMAO levels at 6 months compared with baseline (adjusted p<0.05). …”

Table 3_Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.docx by Xinhui Yang (12051251)

“…Intragroup analysis indicated a significant decrease in TMAO levels at 6 months compared with baseline (adjusted p<0.05). …”

Table 2_Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.docx by Xinhui Yang (12051251)

“…Intragroup analysis indicated a significant decrease in TMAO levels at 6 months compared with baseline (adjusted p<0.05). …”